GOTTO, G. .; DRACHENBERG, D. E. .; CHIN, J. .; CASEY, R. .; FRADET, V. .; SABBAGH, R. .; SHAYEGAN, B. .; RENDON, R. A. .; DANIELSON, B. .; CAMACHO, F. .; ZARDAN, A. .; PLANTE, R. .; HEW, H. .; CHAN, K.; FEIFER, A. . Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC. Canadian Urological Association Journal, [S. l.], v. 14, n. 12, p. E616–20, 2020. DOI: 10.5489/cuaj.6388. Disponível em: https://cuaj.ca/index.php/journal/article/view/6388. Acesso em: 16 apr. 2024.